חוב כולל להון GT Biopharma Corp (GTBP)

The market trend for the total debt-to-equity ratio of GT Biopharma, Inc. (GTBP) stands at 0.00. The firm's financial position relies on clinical test results and external contracts, as there is currently no operating income. Growth potential is based on the TriKE platform, which effectively directs immune cells against leukemias, while the environmental footprint remains minimal due to a virtual drug development format.

For the small biotech company GT Biopharma, Inc. (GTBP), which faces a high burn rate and regulatory risks, controlling the financing structure is critical. By analyzing the total debt-to-equity ratio, an investor assesses the proportion of borrowed funds relative to equity, where a downward trend confirms a reduction in debt load, while an increase indicates dangerous financial leverage that limits business resilience.